Homocysteine-lowering therapy and risk of recurrent stroke, myocardial infarction and death: The impact of age in the VISP trial

Cerebrovascular Diseases

Volumn 37, Issue 4, 2014, Pages 263-267

  Towfighi, Amytis ^a,c   Arshi, Baback ^a,c   Markovic, Daniela ^b   Ovbiagele, Bruce ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Age; Cardiovascular acute events; Cardiovascular disease; Homocysteine; Mortality; Myocardial infarction; Prevention; Stroke; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; COBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; CYANOCOBALAMIN; VITAMIN;

AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE PATIENT; VITAMIN INTAKE; AMINO ACID BLOOD LEVEL; BLACK PERSON; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAROTID ENDARTERECTOMY; CAUCASIAN; CORONARY ARTERY BYPASS GRAFT; MULTICENTER STUDY (TOPIC); OBESITY; PATIENT HISTORY OF SURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SECONDARY PREVENTION; SUBSTITUTION THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; ADULT; METABOLISM; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; RISK FACTOR; STROKE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; STROKE; VITAMIN B 12; VITAMINS;

EID: 84898676268     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000360153     Document Type: Article

References (14)

1. Clarke R, et al: Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med 2010; 170: 1622-1631.
2. Spence JD, Stampfer MJ: Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 2011; 306: 2610-2611.
3. Holmes MV, et al: Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011; 378: 584-594.
4. Rimm EB, Stampfer MJ: Folate and cardiovascular disease: one size does not fit all. Lancet 2011; 378: 544-546.
5. Hsu FC, et al: Transcobalamin 2 variant associated with poststroke homocysteine modifies recurrent stroke risk. Neurology 2011; 77: 1543-1550.
6. Hankey GJ, et al: Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a posthoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 2012; 11: 512-520.
7. Towfighi A, Markovic D, Ovbiagele B: Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: a nationwide study. J Neurol Sci 2010; 298: 153-157.
8. Saposnik G, et al: Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009; 40: 1365-1372.
9. House AA, et al: Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010; 303: 1603-1609.
10. Toole JF, et al: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575.
11. Spence JD, et al: Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 2005; 36: 2404-2409.
12. Spence JD, et al: Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology 2001; 20: 16-25.
13. Lonn E, et al: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577.
14. VITATOPS Trial Study Group: B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke ( VITATOPS) trial: a randomised, doubleblind, parallel, placebo-controlled trial. Lancet Neurol 2010; 9: 855-865.